{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:47:53Z","timestamp":1787327273457,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12282-026-01834-7","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T11:11:12Z","timestamp":1771153872000},"page":"499-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score\u00ae test among node-negative early breast cancer patients in Japan"],"prefix":"10.1007","volume":"33","author":[{"given":"Kei","family":"Koizumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7259-0881","authenticated-orcid":false,"given":"Mark","family":"Gouldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0563-3675","authenticated-orcid":false,"given":"Sandeep","family":"Bilthare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8074-5480","authenticated-orcid":false,"given":"Sebastien","family":"Eymere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-0069","authenticated-orcid":false,"given":"Gebra","family":"Cuy\u00fan-Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9386-8552","authenticated-orcid":false,"given":"Steve","family":"Millen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Drost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Kanazawa","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"1834_CR1","unstructured":"National Cancer Center Cancer Information Service: Projected cancer statistics. 2025. https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_en.html"},{"issue":"1","key":"1834_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41392-024-01779-3","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S, Zhang S, Zhou J. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Therapy. 2024;9(1):83.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"1834_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12282-022-01423-4","volume":"30","author":"K Tada","year":"2023","unstructured":"Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, Kadoya T, Kubo M, Kojima Y, Tanakura K, et al. Characteristics of female breast cancer in Japan: annual report of the National Clinical Database in 2018. Breast Cancer. 2023;30(2):157\u201366.","journal-title":"Breast Cancer"},{"issue":"5","key":"1834_CR4","doi-asserted-by":"publisher","first-page":"e1000279","DOI":"10.1371\/journal.pmed.1000279","volume":"7","author":"FM Blows","year":"2010","unstructured":"Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.","journal-title":"PLoS Med"},{"issue":"6","key":"1834_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prev. 2018;27(6):619\u201326.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1834_CR6","unstructured":"NCCN Guidelines - Breast Cancer: https:\/\/www.nccn.org\/patientresources\/patient-resources\/guidelines-for-patients"},{"key":"1834_CR7","unstructured":"National Institute for Health and Care Excellence, Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719). 2024. . https:\/\/www.nice.org.uk\/guidance\/htg719"},{"key":"1834_CR8","doi-asserted-by":"crossref","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, clinicalguidelines@esmo.org egcea. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(8):1194\u2013220.","DOI":"10.1093\/annonc\/mdz173"},{"issue":"16","key":"1834_CR9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(16):1816\u201337.","journal-title":"J Clin Oncol"},{"issue":"30","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/oxfordjournals.jncimonographs.a003460","volume":"2001","author":"Panel NIoHCD","year":"2001","unstructured":"Panel NIoHCD. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1\u20133, 2000. JNCI Monogr. 2001;2001(30):5\u201315.","journal-title":"JNCI Monogr"},{"issue":"6","key":"1834_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","volume":"30","author":"M Terada","year":"2023","unstructured":"Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, et al. The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer. 2023;30(6):872\u201384.","journal-title":"Breast Cancer"},{"issue":"2","key":"1834_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, et al. Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"23","key":"1834_CR13","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor\u2013positive breast cancer. J Clin Oncol. 2006;24(23):3726\u201334.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1834_CR14","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med"},{"key":"1834_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/1472-6963-14-372","volume":"14","author":"H Yamauchi","year":"2014","unstructured":"Yamauchi H, Nakagawa C, Yamashige S, Takei H, Yagata H, Yoshida A, Hayashi N, Hornberger J, Yu T, Chao C, et al. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan. BMC Health Serv Res. 2014;14:372.","journal-title":"BMC Health Serv Res"},{"key":"1834_CR16","doi-asserted-by":"crossref","unstructured":"Berdunov V, Cuyun Carter G, Laws E, Luo R, Russell CA, Campbell S, Abdou Y, Force J. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score\u00ae test from a US societal perspective. ClinicoEcon Outcomes Res 2024:16 471\u201382.","DOI":"10.2147\/CEOR.S449711"},{"key":"1834_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/CEOR.S360049","volume":"14","author":"V Berdunov","year":"2022","unstructured":"Berdunov V, Millen S, Paramore A, Griffin J, Reynia S, Fryer N, Brown R, Longworth L. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score\u00ae test in node-negative early breast cancer. Clinicoecon Outcomes Res. 2022;14:619\u201333.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"1834_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10549-010-1243-y","volume":"127","author":"M Kondo","year":"2011","unstructured":"Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative\/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat. 2011;127(3):739\u201349.","journal-title":"Breast Cancer Res Treat"},{"key":"1834_CR19","unstructured":"Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council. 2022. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf"},{"issue":"25","key":"1834_CR20","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","volume":"380","author":"JA Sparano","year":"2019","unstructured":"Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395\u2013405.","journal-title":"N Engl J Med"},{"key":"1834_CR21","doi-asserted-by":"crossref","unstructured":"Shimomura A, Sagara Y, Koto R, Fujiwara M, Kanemura Y, Kitagawa H, Saji S. Real-world data of HER2-negative early breast cancer patients treated with anthracycline and\/or taxane regimens in Japan. Breast Cancer (2024) 31: 581-592.","DOI":"10.1007\/s12282-024-01572-8"},{"key":"1834_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41523-018-0090-6","volume":"4","author":"CE Geyer Jr","year":"2018","unstructured":"Geyer CE Jr., Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, Baehner FL, Crager M, Wickerham DL, Costantino JP, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018;4:37.","journal-title":"NPJ Breast Cancer"},{"key":"1834_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-008-0300-2","volume":"117","author":"G De Bock","year":"2009","unstructured":"De Bock G, Putter H, Bonnema J, Van Der Hage J, Bartelink H, Van De Velde C. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat. 2009;117:401\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1834_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10549-012-2121-6","volume":"135","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):335\u201346.","journal-title":"Breast Cancer Res Treat"},{"issue":"10120","key":"1834_CR25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2018","unstructured":"Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572\u201380.","journal-title":"Lancet"},{"issue":"10","key":"1834_CR26","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jval.2017.04.021","volume":"20","author":"PS Hall","year":"2017","unstructured":"Hall PS, Smith A, Hulme C, Vargas-Palacios A, Makris A, Hughes-Davies L, Dunn JA, Bartlett JMS, Cameron DA, Marshall A, et al. Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value Health. 2017;20(10):1311\u20138.","journal-title":"Value Health"},{"key":"1834_CR27","unstructured":"Abridged Life Tables for Japan. 2022. https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/lifetb22\/dl\/lifetb22-06.pdf"},{"key":"1834_CR28","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s12282-021-01239-8","volume":"28","author":"K Inoue","year":"2021","unstructured":"Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, Nakayama T, Mukai H, van der Walt J-S, Mori J. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer. 2021;28:1038\u201350.","journal-title":"Breast Cancer"},{"key":"1834_CR29","doi-asserted-by":"publisher","unstructured":"Taylor CJ, Ord\u00f3\u00f1ez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FDR. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000\u20132017: population based cohort study. BMJ 2019; 364: l223. https:\/\/doi.org\/10.1136\/bmj.l223","DOI":"10.1136\/bmj.l223"},{"key":"1834_CR30","unstructured":"Ministry of Health Labour and Welfare (MHLW). Insurance coverage of medical devices. 2024. https:\/\/www.mhlw.go.jp\/content\/12404000\/001117408.pdf"},{"key":"1834_CR31","unstructured":"Ministry of Health Labour and Welfare (MHLW). Medical fees 2024 and appendix 1 - medical treatment fee schedule 2024. 2024. https:\/\/www.mhlw.go.jp\/content\/12404000\/001065988.pdf, https:\/\/www.mhlw.go.jp\/content\/12404000\/000907836.pdf, https:\/\/www.mhlw.go.jp\/content\/12404000\/000907834.pdf, https:\/\/www.mhlw.go.jp\/content\/12404000\/000907834.pdf"},{"issue":"7","key":"1834_CR32","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/03007995.2021.1927691","volume":"37","author":"R Ueno","year":"2021","unstructured":"Ueno R, Nishimura S, Fujimoto G, Ainiwaer D. Healthcare resource utilization and economic burden of antifungal management in patients with hematologic malignancy in Japan: a retrospective database study. Curr Med Res Opin. 2021;37(7):1121\u201334.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1834_CR33","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1089\/jpm.2020.0649","volume":"24","author":"Y Hashimoto","year":"2021","unstructured":"Hashimoto Y, Hayashi A, Teng L, Igarashi A. Real-world cost-effectiveness of palliative care for terminal cancer patients in a Japanese general hospital. J Palliat Med. 2021;24(9):1284\u201390.","journal-title":"J Palliat Med"},{"issue":"3","key":"1834_CR34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jjcc.2021.10.026","volume":"79","author":"Y Nakao","year":"2022","unstructured":"Nakao Y, Kawakami H, Saito M, Inoue K, Ikeda S, Yamaguchi O. Cost-effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan. J Cardiol. 2022;79(3):408\u201316.","journal-title":"J Cardiol"},{"key":"1834_CR35","doi-asserted-by":"crossref","unstructured":"Report on the Consumer Price Index: 2025 . https:\/\/www.stat.go.jp\/english\/data\/cpi\/1588.html#nen","DOI":"10.69645\/DSDC8304"},{"issue":"5","key":"1834_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/cncr.30421","volume":"123","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y. Comparison of an AC-taxane versus AC\u2010free regimen and Paclitaxel versus docetaxel in patients with lymph node\u2010positive breast cancer: final results of the National Surgical Adjuvant Study of breast cancer 02 trial, a randomized comparative phase 3 study. Cancer. 2017;123(5):759\u201368.","journal-title":"Cancer"},{"issue":"9","key":"1834_CR37","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1001\/jamaoncol.2015.3062","volume":"1","author":"T Fujii","year":"2015","unstructured":"Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis. JAMA Oncol. 2015;1(9):1311\u20138.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1834_CR38","doi-asserted-by":"publisher","first-page":"A449","DOI":"10.1016\/j.jval.2017.08.291","volume":"20","author":"T Iwatani","year":"2017","unstructured":"Iwatani T, Noto S, Tsugawa K. Correlation analysis between health state values derived from EQ-5D-5L and EQ-VAS in Japanese breast cancer patients. Value Health. 2017;20(9):A449\u201350.","journal-title":"Value Health"},{"issue":"7","key":"1834_CR39","first-page":"2113","volume":"117","author":"S Kurosawa","year":"2011","unstructured":"Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, Yamashita T, Watanabe M, Yakushiji K, Yano S. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood J Am Soc Hematol. 2011;117(7):2113\u201320.","journal-title":"Blood J Am Soc Hematol"},{"issue":"17","key":"1834_CR40","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/j.ejca.2011.06.019","volume":"47","author":"HE Campbell","year":"2011","unstructured":"Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer. 2011;47(17):2517\u201330.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1834_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1620\/tjem.2022.J016","volume":"257","author":"F Suzuki","year":"2022","unstructured":"Suzuki F, Sato H, Akiyama M, Akiba M, Adachi O, Harada T, Saiki Y, Kohzuki M. Changes in the quality of life of patients with left ventricular assist device and their caregivers in japan: retrospective observational study. Tohoku J Exp Med. 2022;257(1):45\u201355.","journal-title":"Tohoku J Exp Med"},{"issue":"8","key":"1834_CR42","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193\u2013202.","journal-title":"Value Health"},{"issue":"4","key":"1834_CR43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422\u201337.","journal-title":"Health Econ"},{"key":"1834_CR44","unstructured":"National Institute of Public Health. Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. 2022."},{"key":"1834_CR45","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press; 2015."},{"key":"1834_CR46","unstructured":"Projected cancer incidence in 2023: 2023. https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_en.html"}],"updated-by":[{"DOI":"10.1007\/s12282-026-01905-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000}}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01834-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01834-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01834-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:43:16Z","timestamp":1787323396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01834-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01834-7","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12282-026-01905-9","URL":"https:\/\/doi.org\/10.1007\/s12282-026-01905-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mark Gouldson, Sandeep Bilthare, Sebastien Eymere, Mariko Nomoto and Yoshie Onishi: All were employed by Putnam at the time of writing and have received funding from Exact Sciences. Gebra Cuyun Carter, Steve Millen, Aki Kudo, Pieter Drost, Tom Kanazawa Tang and Naoko Sugiyama: employees and stockholders of Exact Sciences. Kei Koizumi, Ataru Igarashi and Naoki Niikura: served as paid advisors for Exact Sciences.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a modelling study which did not require ethics approval.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was not required as all data used was obtained from published clinical trials and publicly available sources, except when provided by clinical experts. The Clinician Expert Survey study was an opinion survey, based on the clinical experience of oncologists experienced in the treatment of early breast cancer in the adjuvant setting in Japan. Participating clinicians were aware it was an opinion survey study and agreed that the aggregated information would be used to provide up-to-date information related to current clinical practice for cost-effectiveness modelling. No individual patient data was used in the conduct of the study and therefore it was determined by the study coordinator that no ethics approval or formal waiver was required.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}